Not Yet Recruiting PHASE1 Interventional 1-arm NCT03368222

Pembrolizumab and SBRT in Metastatic Non-small-cell Lung Cancer Patients (PRIMING)

Phase I Study Combining PembRolIzuMab and Hypofractionated Stereotactic Radiotherapy In Patients With Metastatic Non-small-cell lunG Cancer

Sponsor: Merck Sharp & Dohme Corp.

Conditions NSCLC NSCLC Stage IV NSCLC, Stage IIIB Non Small Cell Lung Cancer

Interventions Pembrolizumab Sterotactic Body Radiotherapy

Updated 2 times since 2017 Last updated: Dec 8, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03368222, this PHASE1 trial focuses on NSCLC and NSCLC Stage IV and remains actively recruiting participants. Sponsored by Merck Sharp & Dohme Corp., it has been updated 2 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

2 versions recorded

Jun 2018 — Present [monthly]

Not Yet Recruiting PHASE1
Dec 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme Corp.
Royal Marsden NHS Foundation Trust

Data source: Royal Marsden NHS Foundation Trust

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.